期刊
JOURNAL OF RHEUMATOLOGY
卷 41, 期 11, 页码 2120-2128出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.140238
关键词
FOSTAMATINIB; METHOTREXATE; EFFICACY; OSKIRA; RHEUMATOID ARTHRITIS
类别
资金
- AstraZeneca
- AbbVie
- Amgen
- Augurex
- BMS
- Celgene
- Centocor
- Chugai
- Covagen
- Roche
- Sanofi-Aventis
- Schering-Plough
- UCB
- Vertex
- Abbott
- Baylis Medical
- Bristol-Myers Squibb
- Janssen
- Eli Lilly and Co.
- Novartis
- Pfizer
- Servier
- RottaPharm
- Astellas
- Genentech
- Crescendo Bioscience
- Ablynx
- Adheron Therapeutics
- Antares
- Canfite
- Ensemble
- Exagen
- Five Prime
- Genentech/Roche
- Hutchison
- Idera
- Infinity
- Lycera
- Lilly
- Medimmune
- Merck
- Novo Nordisk
- Regeneron
- Daiichi
- GSK
- Otsuka
Objective. Our 24-week study (NCT01197755; OSKIRA-3) compared the efficacy and safety of fostamatinib versus placebo in patients taking background methotrexate treatment with active rheumatoid arthritis (RA) and an inadequate response to a single tumor necrosis factor-alpha antagonist. Methods. Adult patients were randomized (1: 1: 1) to fostamatinib [100 mg bid for 24 weeks (n = 105; Group A)], or 100 mg bid for 4 weeks, then 150 mg qd (n = 108; Group B), or to placebo (n = 110; Group C) for 24 weeks. Nonresponders at Week 12 could enter a longterm extension study. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20% (ACR20) response at Week 24. Results. Baseline characteristics were well balanced. Significantly more patients in fostamatinib Group A (36.2%; p = 0.004), but not B (27.8%; p = 0.168), achieved ACR20 at Week 24 versus placebo (21.1%). Frequently reported adverse events were diarrhea, hypertension, and headache. Elevated blood pressure (>= 140/ 90 mm Hg) at >= 1 visit was observed in 46.7%, 51.9%, and 26.6% of patients, respectively. There were 2 deaths in the study, 1 in Group B and 1 in the placebo group. Conclusion. Fostamatinib 100 mg bid, but not fostamatinib 100 mg bid for 4 weeks then 150 mg qd, achieved statistical improvements in ACR20 at 24 weeks versus placebo. Because of efficacy and safety results from the phase III clinical program, the companies developing fostamatinib have decided not to study it further in RA at this time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据